NexGard COMBO for cats EMA marketing authorization
Boehringer Ingelheim received marketing authorization from the EMA (European Medicine Agency) for its NexGard® COMBO topical solution for cats.
Search
Behavioral science to improve cattle well-being
Boehringer Ingelheim kicks off a project based on behavioral science to improve cattle well-being
Boehringer Ingelheim partners with GNA Biosolutions
Boehringer Ingelheim partners with GNA Biosolutions to develop African swine fever diagnostic test.
Matthias Muenks
Matthias Muenks, Global Engineering Process and Data Manager, speaks about our innovation and culture.
Boehringer receives SBTi validation for CO2 reduction targets
Boehringer Ingelheim receives SBTi validation for CO2 reduction targets
Second cancer immunotherapy partnership with 3T Bio
Second cancer immunotherapy partnership with 3T Bio
FreVAX smartphone application piglet vaccination
New FreVAX™ smartphone application brings piglet vaccination to another level
Positive opinion Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU
Boehringer Ingelheim receives positive opinion for the combined use of Ingelvac CircoFLEX® and Ingelvac PRRSFLEX EU® in the EU
DiaTEC new purification technology Ingelvac CircoFLEX
Boehringer Ingelheim introduces DiaTEC, a new and proprietary purification technology for Ingelvac CircoFLEX®
Boehringer Ingelheim annouces 2020 BVDzero Case Awards
Boehringer Ingelheim is announcing the 2020 ‘BVDzero Case Awards’ are now open for applications. The bi-annual awards reflect the long-term commitment to promoting the health and well-being of farm animals.
Partnering with Constantia Flexibles for augmented reality
Boehringer Ingelheim partnered with Constantia Flexibles to provide an innovative packaging solution which enhances the Nutraxin packaging with augmented reality features.
12th Expert Forum on Farm Animal Well-Being
The 12th Expert Forum on Farm Animal Well-Being brought together over 100 industry experts
commitments to sustainable development
On One Health Day, Boehringer Ingelheim shares an update on its strategic approach to sustainability for employees, partners and wider communities
Targeting HER2 in cancer: The story of zongertinib
We discovered zongertinib, an HER2 tyrosine kinase inhibitor, being developed as a potential oral treatment for people with HER2-mutated NSCLC
university-of-medical-excellence-harvard
A program designed by Harvard Medical School Executive Education with the goal of accelerating clinical development and medical affairs
Making more health through animal health
Boehringer Ingelheim and Ashoka aim to build a world with a greater access to health for people, animals and their communities.
world rabies day 2019
world rabies day 2019
Diabetes dog symptoms chronic disease management
Learn about the symptoms of canine diabetes and how to manage the disease.
Boehringer biopharmaceuticals China receives approval supply EU and US
Boehringer Ingelheim Biopharmaceuticals China receives approval for supply of EU and US markets
global-top-employer
For the first time, Boehringer Ingelheim receives the award as a Global Top Employer as well as individual awards in 27 countries.
EMA authorization for Reprocyc ParvoFLEX
Boehringer Ingelheim obtains EMA authorization for Reprocyc® ParvoFLEX, a new porcine parvovirus vaccine
Winners of the 2019 European PRRS Research Award
Winners of the 2019 European PRRS Research Award announced.
Boehringer Ingelheim opens Health Management Centre in China
Boehringer Ingelheim opens Health Management Centre in China The new Health Management Centre integrates animal disease and health diagnostics as well as monitoring tools The centre further strengthens the company’s ability to provide services along the f
Winners of 2020 BVDzero Case Awards
Winners of 2020 BVDzero Case Awards announced. 10 top clinical cases will receive a total prize of 15,000 euros.
Boehringer expands production site in Greece
Boehringer expands production site in Greece for new medicine